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Abstract
Purpose
This study evaluates the diagnostic accuracy of [F-18]-fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (FDG-PET/CT) of the chest/upper abdomen com-
pared to the generally performed scan from head to upper thighs, for staging and
management of (suspected) lung cancer in patients with no history of malignancy or com-
plaints outside the thorax.
Methods
FDG-PET/CT scans of 1059 patients with suspected or recently proven lung cancer, with
no history of malignancy or complaints outside the thorax, were analysed in a retrospective
multi-centre trial. Suspect FDG-avid lesions in the chest and upper abdomen, the head and
neck area above the shoulder line and in the abdomen and pelvis below the caudal tip of the
liver were noted. The impact of lesions detected in the head and neck area and abdomen
and pelvis on additional diagnostic procedures, staging and treatment decisions was
evaluated.
Results
The head and neck area revealed additional suspect lesions in 7.2%, and the abdomen and
pelvis in 15.8% of patients. Imaging of the head and neck area and the abdomen and pelvic
area showed additional lesions in 19.5%, inducing additional diagnostic procedures in
7.8%. This resulted in discovery of additional lesions considered malignant in 10.7%,
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changing patient management for lung cancer in 1.2%. In (suspected) lung cancer, PET/CT
limited to the chest and upper abdomen resulted in correct staging in 98.7% of patients,
which led to the identical management as full field of view PET in 98.8% of patients.
Conclusion
High value of FDG-PET/CT for staging and correct patient management is already achieved
with chest and upper abdomen. Findings in head and neck area and abdomen and pelvis
generally induce investigations with limited or no impact on staging and treatment of
NSCLC, and can be interpreted accordingly.
Introduction
Lung cancer is diagnosed in an estimated 386.300 patients annually in Europe and in an esti-
mated 1.8 million patients worldwide in 2012, and will continue to be a significant epidemic in
the coming decades [1,2]. Prognosis is generally poor as most patients present with an
advanced stage of the disease, with an overall 5-year survival of only 15% [3]. Therapeutic strat-
egies with curative intent are available for selected subgroups [4]. Early detection and accurate
evaluation of disease extent are essential to ensure appropriate treatment.
Detection and staging of lung cancer generally involves staging modalities such as, chest X-
ray, CT-scans, bronchoscopy, echo-endoscopy, sonograhy of the abdomen, mediastinoscopy,
PET-scan, each having a specific value which all can contribute to the staging [5,6]. To achieve
quick and accurate staging at an acceptable cost and patient burden, multiple diagnostic proce-
dures need to be combined in an optimal strategy.
Imaging for detection and staging of lung cancer is traditionally based on computed tomog-
raphy (CT) of the thorax [7]. In many cases the diagnostic algorithm is extended with “whole
body” positron emission tomography using [F-18]-fluorodeoxyglucose (FDG-PET), for non-
invasive staging based on metabolic tissue characterization [8]. FDG-PET is integrated into
clinical management as it has proven to be highly sensitive and specific for detection of lymph
node metastases and distant metastases and it characterizes indeterminate lesions detected on
CT [9–12]. CT and FDG-PET provide additive diagnostic information, nowadays acquired in a
single session with integrated PET/CT scanners [13–15]. But PET/CT has not replaced CT for
staging lung cancer.
CT for detection and staging of lung cancer has been standardized to fully include the struc-
tures of the thorax (ie thoracic inlet and inferior pleural reflections) which generally comprises
a scanning field of view from the lower neck to the upper abdomen. This field of view includes
the site of the primary tumour, possible locations of lymph node metastases (e.g. the lung hilus,
mediastinum and supraclavicular regions) and many sites prone to distant metastases (e.g. the
contralateral lung, the adrenal glands, a significant part of the liver and a large proportion of
the axial skeleton) [16]. Sometimes an additional CT or MRI scan of the brain is performed to
assess brain metastases. Body parts with a low diagnostic yield for this specific clinical applica-
tion are generally not imaged with CT, such as the lower abdomen and pelvis, the arms, and
the legs.
In contrast, FDG-PET for the detection and staging of lung cancer is traditionally per-
formed in a “whole body” setting, although the exact scan field of view varies per institute, e.g.
full body (head to toe) or only the central body (base of the skull to the upper thighs). It is well
known that FDG-PET may reveal unexpected distant metastases or second primary tumours
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[11,17,18]. On the other hand, the rate of false-positive PET lesions in the head/neck and lower
abdomen/pelvis may be relatively high, resulting in undesired treatment delays and patient
stress due to additional investigations.
In this study we investigated the diagnostic value of FDG-PET/CT for the detection and pri-
mary staging of lung cancer, with and without body areas with a low pre-test likelihood of met-
astatic lesions.
Materials and Methods
Patients
All patients who were referred for lung cancer evaluation between September 2006 and Sep-
tember 2007 in 5 participating centers were eligible for inclusion (Table 1). Inclusion criteria
were: suspected or recently proven lung cancer (either NSCLC or SCLC), referred for
FDG-PET/CT imaging for tumour detection or staging, no history of prior malignant disease,
and no signs or symptoms of malignant disease outside the thoracic area. Prior diagnostic
imaging with other modalities (e.g. CT, bone scan) was not an exclusion criterion, as long as no
distant metastases were suspected prior to FDG-PET/CT.
The study has been carried out in the Netherlands in accordance with the applicable rules
concerning the review of research ethics committees and informed consent.
We received a waiver of approval from the CMO region of Arnhem-Nijmegen. Consent was
not needed to be obtained, as this was a retrospective study with anonymously analyzed data.
The data was collected by AIJA, JWAP, WMJS, AL, BWH andWVV. The authors anonymized
the data themselves. Some of the authors might have had interaction with some of the patients
discussed within the study but not in context of the study, this interaction would only be the
administration of FDG prior to the scan.
FDG-PET/CT imaging
Scanner types, scan field of views and imaging protocols in the participating institutes are listed
in Table 1. Local imaging protocols for the detection and staging of lung cancer were respected,
as they reflect the current clinical practice in the Netherlands. A minimum scan field of view
from the skull base to the upper thighs was required for FDG-PET/CT. FDG-PET/CT was
Table 1. Institutes and imaging protocols.
Participants PET imaging CT imaging
Institute Location PET/CT device Scan Field of
view
FDG dose
(MBq)
Scan time
(min/bp)
Reconstruction
parameters
Scan parameters
BVI Tilburg Siemens
Biograph 2
GE discovery
STE16
Skull top-
groins
Skull top-
groins
4.2/kg
4.2/kg
3.00
3.00
OSEM 2i 8s
OSEM 2i 20s
Lowdose 30 mAs
Lowdose 40 mAs
Atrium MC Heerlen Philips Gemini Skull top-
groins
3.7/kg 3.00–5.00 OSEM 2i 8s CE Diagnostic 100
mAs
Radboud university
medical center
Nijmegen Siemens
Biograph 2
Skull base-
groins
3.5/kg 4.00 OSEM 2i 8s Lowdose 40 mAs
Rijnstate Hospital Arnhem Philips Gemini Skull top-
groins
3.125/kg 1.45 LOR-RAMLA Lowdose 40 mAs
NKI-AvL hospital Amsterdam Philips Gemini
TOF
Skull base-
groins
3/kg 2.15 TOF default Lowdose 40 mAs
TOF = time of ﬂight. CE = Enhanced with intravenous contrast.
doi:10.1371/journal.pone.0160539.t001
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performed after at least 4 hours of fasting. Diabetes mellitus needed to be regulated with fasting
glucose levels< 11 mmol/l (<200 mg/dl), with no insulin administration shortly prior to FDG
administration. Some centers performed low-dose CT, whilst one institution performed diag-
nostic quality contrast-enhanced CT of the whole scanning field of view.
Image evaluation
The nuclear medicine physicians (AIJA, JWAP, WMJS, AL, BWH, andWVV with 5, 2, 5, 1, 5,
and 7 years of experience with FDG PET, respectively) independently and unblinded evaluated
the existing reports of their own institution, and evaluated reported lesions. For each scan the
presence and amount of lesions in three regions were documented. The head and neck area
(HN): all above the shoulder line. The lower abdominal and pelvic area (LAP): all below the
caudal tip of the right liver lobe. The region between HN and LAP (thoracic range) is the region
of interest for imaging of (suspected) lung cancer (Fig 1).
Fig 1. Scan regions. The regions evaluated in this study. The head and neck area (HN): all above the
shoulder line. The lower abdominal and pelvic area (LAP): all below the caudal tip of the right liver lobe. The
region between HN and LAP (chest and upper abdomen, thoracic range) is the region of interest for imaging
of (suspected) lung cancer.
doi:10.1371/journal.pone.0160539.g001
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Image analysis
The PET/CT findings were evaluated for (1) the impact of detected lesions in HN and LAP in
change on staging, (2) PET-driven additional diagnostic procedures and (3) the impact on
patient management by analysis of medical files and/or consultation of the referring pulmonol-
ogist, reflecting the use of PET/CT in clinical practice.
Lesions reported on FDG-PET/CT that were considered clinically irrelevant (i.e. did not
result in any clinical effect or analysis for the management of the initial index lung lesion
within 3 months after performing the FDG-PET/CT scan) were considered “ignored” and thus
not relevant in the process of the patients’ work-up and treatment for lung cancer. Lesion-
based analyses were performed separately for the HN and LAP areas, and on a patient basis
(for the combined HN-LAP areas).
Results
The 5 participating centers included a total of 1059 patients (668 male and 381 female; average
age 64 years, range 31–100 years). In 207 patients (19.7%), one or more FDG-avid lesions
indicative of distant metastases or a second primary tumour in either the HN or LAP area were
indicated in the report (Table 2).
In the HN area, suspect FDG-avid lesions were identified in 7.2% of the patients. In 3.2% of
patients metastatic disease from lung cancer in the HN area was considered based on PET, con-
firmed by additional investigations. This resulted in upstaging in only 0.5% and changed therapy
(i.e. from surgery to chemotherapy, from chemotherapy with curative intend to chemotherapy
with palliative intend) in 0.4%. Positive findings consisted of metastases in high cervical lymph
nodes and the brain. Skeletal metastases were also detected in HN, but none of these upstaged
the patient as they all had multiple distant metastases in the thoracic field of view. In addition,
someWarthin tumours, benign thyroid nodules and benign lymph nodes were identified, but
no proven second primary tumours in the HN area were detected (Fig 2). Altogether only one
third of the suspected PET lesions was further evaluated. Nearly half of the lesions were consid-
ered clinically irrelevant or considered benign in the context of findings on the scan of a patient
with a lung tumor.
In the lower abdomen/pelvic area, suspect FDG-avid lesions were identified in 15.8% of the
patients. From all patients, 9.0% was considered to have metastatic disease from lung cancer in
the LAP area based on PET, confirmed by additional investigations. This resulted in upstaging of
only 0.8% of patients and changed therapy in 0.8%. Patients were upstaged due to metastases in
the lumbar spine and pelvis, psoas muscle, adnex, subcutaneous tissue, and mesenterium. In
addition, 4 clinically silent colon carcinomas, 1 bladder cancer, 1 schwannoma, and 1 unspecified
Table 2. FDG PET-findings summarised by scan area.
Scan
area
Patient based analysis of imaging results Impact on lung cancer Other ﬁndings
suspect
PET
Additional
tests
Neglected /
benign
Proven
mets
Impact on
stage
Impact on
treatment
Conﬁrmed benign
disease
Conﬁrmed second
primary
HN 7.2% 2.4% 3.3% 3.2% 0.5% 0.4% 0.7% 0%
LAP 15.8% 5.7% 4.1% 9.0% 0.8% 0.8% 2.7% 0.7%
HN
+LAP
19.5% 7.8% 6.1% 10.0% 1.3% 1.2% 3.4% 0.7%
HN = head/neck area. AP = lower abdominal and pelvic area. HN+LAP = in either the HN or the LAP area. All listed percentages are relative to the total
patient cohort.
doi:10.1371/journal.pone.0160539.t002
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abdominal malignancy were detected and subsequently proven (total 0.7% of patients), as well as
numerous benign bowel polyps (Fig 3). Compared to HN, the LAP region showed more lesions,
but had a similarly low impact on patient management for lung cancer.
In total, the classical “full field of view” (the whole body) FDG-PET/CT migrated stage in
only 14 of 1059 patients (1.3%) due to the inclusion of the HN and LAP (for non-small cell
lung cancer 3 patients from stage IIb to IV, 2 from IIIa to IV, 5 from IIIb to IV, and 2 from
unspecified to IV, and for small cell lung cancer 2 patients from limited to extensive disease).
The treatment of thirteen patients (1.2%) changed from curative to palliative intent; the
remaining patient being upstaged was already considered for palliative treatment for other rea-
sons. This indicates that when limiting the FDG-PET/CT scan field of view to ‘thoracic range’
results in correct staging in 98.7% of patients and identical management as full field of view
PET/CT in 98.8% of patients.
There was no significant difference between institutes that included (in 718 patients) or
omitted the brain (in 341 patients) (reported lesions in HN and LAP in 20.9% (24.3%-13%-
25.4%) versus 19.3% (19.1%-19,6%), and impact on therapy 1.4% (1.6%-0%-2.7%) versus 1%
(1.2%-0.7%)). The institute that performed whole body contrast-enhanced high dose CT in all
patients (in a total of 264 patients versus the other 795 patients) reported more lesions (25.4%),
but this did not result in more upstaging (1.1%).
Due to the additional FDG-PET/CT results in HN and LAP, a total of 96 additional investi-
gations was ordered, with estimated total costs of €25,360 (Table 3). As only 14 patients were
upstaged and another 7 patients were diagnosed with a second primary tumour, most of these
investigations were performed for lesions that turned out to be benign or with little clinical rel-
evance. The costs for additional investigations generated by FDG-PET/CT were relatively low
Fig 2. Example head/neck area. Significant false-positive finding on PET/CT in the head/neck area. Intense
FDG uptake in a lymph node (red arrow), revealing inflammation in a patient who eventually did not have lung
cancer. Bowel-hotspots were ignored (blue arrows). Left: maximum intensity projection of PET. Right:
Corresponding transverse slices of PET (top), PET/CT (middle), and CT (bottom).
doi:10.1371/journal.pone.0160539.g002
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for the entire population (€25,360 / 1059 = €24 per patient). The additional costs per patient
upstaged or diagnosed with a second primary tumour were €1208 (€25,360 / 21).
Discussion
The added value of FGD-PET(/CT) imaging for characterization and staging of lung cancer is
undisputed [20]. The procedure allows adequate non-invasive characterization of lung nodules,
Fig 3. Example abdominal/pelvic area. True-positive but no-impact findings on PET/CT in the lower
abdominal and pelvic area. Multiple skeletal metastases were detected (blue arrows), but these had no
impact on staging as the thoracic field of view already showed multiple distant metastases (skeletal, adrenal
glands, liver). An intense bowel hotspot (red arrow) is probably a colon carcinoma or large dysplastic polyp,
but this was ignored as the prognosis of this patient was determined by the lung cancer. Imaging of the lower
abdomen and pelvic area did not change the stage or therapy for this patient. Left: Coronal maximum
intensity projection of PET. Right: Corresponding transverse slices of PET (top), PET/CT (middle), and CT
(bottom).
doi:10.1371/journal.pone.0160539.g003
Table 3. Additional investigations.
Additional investigations Costs per unit (€)[19] Number performed Total cost (€)
Biopsy 50 18 900
Ultrasound 60 17 1,020
Bone scan 160 4 640
CT 200 4 800
MRI 200 21 4,200
Endoscopy 350 28 9,800
Operation 2,000 4 8,000
Total 96 25,360
The number of additional investigations performed for suspect FDG-avid lesions as seen on whole body FDG-PET/CT in the head/neck (HN) and lower
abdomen/pelvis (LAP) areas of patients referred for evaluation of (suspected) lung cancer.
doi:10.1371/journal.pone.0160539.t003
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improves the accuracy of staging for lymph nodes and distant metastases, reduces the number
of unnecessary invasive procedures such as mediastinoscopy and thoracotomy, allows better
determination of prognosis, may improve therapy outcome, and is cost-effective [8,9,11,21–
28]. Here, we have focused on the primary evaluation of lung nodules and primary staging of
lung cancer in patients without a history of prior malignancy or symptoms of disease activity
outside of the chest area. We chose for a multi-centre setting including a dedicated cancer
clinic, a university hospital and general hospitals to evaluate the feasibility of a shorter scan
field of view for PET/CT to avoid variations in locally applied imaging protocols for PET/CT.
We showed that the high diagnostic accuracy is achieved in the ‘thoracic range’ area, while the
FDG-PET findings of the HN and LAP areas have very limited clinical impact and may even
result in unwanted delays and futile additional tests.
The total number of lesions suspect for malignancy outside the thoracic area was quite high
(almost 20% of patients), but only a very limited fraction of these lesions had a clear clinical
impact. Many findings were not of additional value even though there was clear suspicion or
proof of metastatic disease, because imaging of the thoracic field of view had already estab-
lished stage IV disease. This was notably true for skeletal metastases in the lumbar spine or cer-
vical spine, which occurred relatively frequently (10%), but hardly ever without concurrent
metastases in the thoracic spine or ribs (only in 0.2%).
A large part of the suspect PET-findings in HN and LAP was not further evaluated (almost
one third of the described lesions), mainly because they were considered clinically irrelevant
given the detected presence of (metastasized) lung cancer within the thoracic scanning field of
view. From the evaluated lesions, many were found to be benign and irrelevant for staging after
sometimes costly additional investigations (in 6.1% of patients, or nearly one third of the
described lesions), and may have delayed the start of appropriate therapy for lung cancer. This
reflects the balance between the very high sensitivity and relatively limited specificity of
FDG-PET even when using an integrated PET/CT scanner, and the relatively low pre-test like-
lihood of metastatic disease from lung cancer in the HN and LAP regions [29]. Our results are
in agreement with Marom et al., who previously reported that FDG-PET/CT for thoracic
malignancies may reveal many irrelevant FDG-avid lesions outside the thorax, and Lardinois
et al. who confirmed that about half of such lesions are indeed benign or clinically irrelevant
[30,31].
Second primary malignancies occur relatively frequently in patients with lung cancer, and
the ability of FDG-PET to detect these is well known [18]. Treating lung cancer while another
malignancy remains undetected can be considered oncologically undesirable, and for this rea-
son many consider whole body PET essential. Our series featured lesions suspected of possible
second malignancies in several cases, of which only a small part was actually considered onco-
logically relevant (0.7%). This number is remarkably similar to the detection rate of cancer
(0.97%) reported by Minamimoto et al, using PET/CT in the cancer screening study in 50558
patients in Japan [32]. Gutman et al. also found that only a few of the most intense hotspots of
a large number of bowel hotspots represented second primary malignancies [33]. Thus, second
primaries may be detected by FDG-PET, but in many cases these are clinically irrelevant in the
presence of (metastasized) lung cancer, while requiring quite a number of additional investiga-
tions per positive result. Although not specifically addressed in our retrospective analysis, it
can be imagined that false-positive or clinically irrelevant FDG-PET findings may contribute
to prolonged patient stress in the diagnostic period prior to the start of therapy, e.g. due to
delays or physical discomfort due to additional invasive procedures (e.g. colonoscopy, biopsy).
A possibly negative effect of a diagnostic delay of up to several weeks on the final oncological
outcome of lung cancer is difficult to assess, but may occur in a (limited) number of cases.
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Using stand-alone FDG-PET, Reed et al found unexpected distant metastases in 5.2% of
patients with lung cancer who were initially considered operable [23]. However, these relevant
metastases may not be distributed evenly in the body. Acquino et al demonstrated that thoracic
field of view FDG-PET has sufficient value, and that extending to wholebody FDG-PET hardly
has any impact on staging of lung cancer although it detects more metastases [34]. Our findings
confirm that the same hold true for integrated PET/CT, although some methodological differ-
ences exist. We did not exclude small cell lung cancer or non-confirmed PET findings, in order
to reflect daily clinical practice without selection bias. The use of integrated PET/CT instead of
a separate PET most likely excluded several false positive findings [35]. We feel these results
represent the current situation in most diagnostic centers.
Some clinicians regard the FDG-PET/CT as the most efficient imaging modality and would
rather use it as a “one-stop-shop” and achieve as much information as possible in one session
via whole body imaging in all patients. However, we believe the application of any imaging pro-
tocol needs to be tailored to clinical demands. Customizing PET imaging protocols to specific
clinical questions has been suggested for many situations. Examples are extension of the scan-
ning field of view to a full head-to-toe in melanoma and multiple myeloma or a very limited
scan field of view with optimized acquisition and reconstruction parameters in the head and
neck area [36,37]. Other examples of customized protocols include delayed imaging of e.g.
brain tumours or dual time point imaging for discrimination of tumour and inflammation
[38,39].
Conclusion
We conclude that staging of newly diagnosed or suspected lung cancer with FDG-PET/CT is
very accurate when evaluating the thorax and upper abdomen. Expanding the field of view to
include the head and neck, and lower abdominal and pelvic field of view may reveal additional
information, but also induces oncologically irrelevant additional investigations and delays with
very limited impact on patient management. Therefore, additional positive findings outside the
chest and upper abdomen should be reported with extreme caution.
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